CClinicalTrials.gg
CompletedNCT02457195GTPPONVUpdated Dec 18, 2019Results posted

Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting

A Phase 2 interventional study of granisetron in Postoperative Nausea and Vomiting, sponsored by Milton S. Hershey Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by Milton S. Hershey Medical Center · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

The objective of the study is to evaluate the efficacy and safety of adding transdermal preparation of granisetron (Sancuso ®) to the current postoperative nausea and vomiting (PONV) standard prophylaxis regimen with dexamethasone and ondansetron in patients with the previous history of severe, particularly delayed and/or post-discharge, PONV and undergoing surgical procedure under general anesthesia.

The specific aims of the study include:

  1. efficacy of the investigated therapy in prevention of PONV up to 120 hours after surgery
  2. incidence and seriousness of the observed side effects
  3. ability of patients to self-administer preoperatively and maintain the investigated patch during the perioperative period
  4. level of satisfaction with the preoperative PONV prophylaxis.
Read the detailed description

Patients will be recruited from the surgical population undergoing preoperative evaluation in Anesthesiology Preoperative Evaluation Clinic at Hershey Med. Ctr. (\~15,000 per year). Selected patients (ASA 1-3, N=60) with history of severe PONV after one or more of previous general anesthesia, and scheduled to undergo surgical procedures with general anesthesia will be enrolled into IRB approved protocol. The patch will be placed by the patient at home 24 - 48 hours before surgery as directed by the doctor. The subsequent standardized general anesthesia protocol for elective surgery will include general endotracheal anesthesia with sevofluran, including standard intraoperative PONV prophylaxis (IV dexamethasone and IV ondansetron, each 4 mg). Postoperative evaluation will include recording of incidence and severity of PONV at the time of discharge from PACU (acute PONV), at 24 hr, 48 hrs, 72 and 120 hrs (delayed or post discharge PONV).

7.2.1 Visit 1 - Anesthesia Preoperative Evaluation Clinic and recruitment and drug dispensation Patient is seen in clinic and identified as having a history of serious PONV, in particular delayed or post discharge PONV. Study will be explained to the patient and consent obtained. The investigational pharmacy will be notified that a study patient has been enrolled and they will prepare the patches for distribution to the patient.

A member of the research team will obtain the assigned patches from the investigational pharmacy and deliver to the anesthesia provider (member of the research team).

The provider will then demonstrate to the patient how to apply the patch and the patient can practice using a placebo patch to show that the correct placement. Patient will then take the actual patch home with them.

7.2.2 Visit 2 - approximately 24-48 hours preoperatively (patient's home) Patient will apply the patch to their upper arm 24-48 hours before scheduled surgical procedure, as instructed during their pre-op anesthesia visit. The patch will then remain in place until 120 hours after surgical procedure. No backup patch will be provided so the patients with the accidently missing patch will need to call their primary surgical service for the standard antiemetic medication.

7.2.3 Visit 3- Day of Surgery Patient will arrive for surgery. A member of the research team will meet them in the SDU and record the time that the patch was applied, and if it has been placed correctly, intact and still in place. Any potential side effects (systemic or local) will be recorded at that time. The subsequent standardized general anesthesia protocol for elective surgery will include general endotracheal anesthesia with sevofluran (no nitrous oxide), muscle relaxants (with reversal), intraoperative IV opioid analgesics, including standard PONV prophylaxis (dexamethasone and ondansetron IV 4 mg).

Early postoperative evaluation will include recording of incidence and severity of PONV at the time of discharge from PACU (acute PONV). The incidence of vomiting or retching will recorded by the nursing staff. Patients with symptoms requiring a rescue antiemetic-nausea score ≥4 on an 11-point Numeric Rating Scale (NRS), retching or vomiting, or patient request-within 6 hours of PACU admission will be given the rescue medication (Benadryl or promethazine). The NRS was an 11-point linear scale on which patients rated their nausea, with 0 meaning no nausea and 10 meaning the worst possible nausea.

The subsequent evaluations will be performed either at the patient's bed (if in the hospital) or by phone call at 24 hr, 48 hrs, 72 and 120 hrs (delayed or post discharge PONV). The patient will be supplied with a diary to record the information that will be requested on the follow-up phone calls.

The primary efficacy endpoint will be complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure and the change from baseline nausea score using the NRS. Treatment-emergent adverse events (TEAEs), regardless of suspected causal relationship to the study medication, will be also recorded throughout and continued until 5 days after surgery.

7.3 Duration of Participation Patient will remain in the study until all time points have been met (maximum 5 days following surgery or 120 hours). At the end of the study the patient will remove and dispose the remaining patch.

02

Conditions studied

  • Postoperative Nausea and Vomiting

Keywords

  • PONV
  • anesthesia
  • granisetron
03

In context

Nausea

822 studies on the registry are indexed under Nausea; 104 are open to participants now.

This study's enrollment of 50 is below the median of 115 across 703 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 480 studies on the registry; 61 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 42 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients that are between the ages of 18 and 89
  • Scheduled to undergo surgical procedures with general anesthesia
  • Seen in the anesthesia clinic at least 24 hours before surgery
  • History of severe PONV after previous general anesthesia
  • Surgical procedures with anticipated duration > 1 hour and no more than 5 hours
  • American Society of Anesthesiologists (ASA) physical status I to III

Exclusion criteria

Exclusion Criteria:

  • Allergy to granisetron or other 5HT3RA drugs
  • Previous allergic reactions to any drug skin patches
  • Recent (less than 1 month) or current chemo- or radiotherapy
  • Any nausea, vomiting, or retching within 24 hours prior to anesthesia
  • Any type of eye surgeries
  • History or diagnosis of gastrointestinal obstruction or ileus
  • History of serotonin syndrome
  • Unable to sign consent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Admnistration of granisetron

    Preoperative administration of granisetron transdemal patch

    Drug: granisetron

Interventions

  • Druggranisetron

    Application granisetron transdermal patch preoperatively

    Also known as: Sancuso

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea

    Composite measure consisting of complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure.

    Time frame: 24 hrs, 48 hrs, 72 hrs and 120 hrs

07

Results

Posted Apr 16, 2019

Participant flow

Participant flow — Overall Study
MilestoneAdmnistration of Granisetron
Started50
Completed41
Not completed9
Withdrew: Adverse event3
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryNumber of Participants With Complete Response (CR), No PONV Symptoms, Nausea

Composite measure consisting of complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure.

Time frame:
24 hrs, 48 hrs, 72 hrs and 120 hrs
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea
ParticipantsAdmnistration of Granisetron
Completed Response : 24 hrs8
Completed Response : 48 hrs25
Completed Response : 72 hrs24
Completed Response : 120 hrs28
No PONV symptoms : 24 hrs18
No PONV symptoms : 48 hrs25
No PONV symptoms : 72 hrs24
No PONV symptoms : 120 hrs28
Nausea : 24 hrs21
Nausea : 48 hrs11
Nausea : 72 hrs7
Nausea : 120 hrs3
Vomiting with or without retching : 24 hrs5
Vomiting with or without retching : 48 hrs2
Vomiting with or without retching : 72 hrs0
Vomiting with or without retching : 120 hrs0
Retching (dry-hives, without vomiting) : 24 hrs3
Retching (dry-hives, without vomiting) : 48 hrs1
Retching (dry-hives, without vomiting) : 72 hrs0
Retching (dry-hives, without vomiting) : 120 hrs0

Adverse events

Collected over 120 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Admnistration of Granisetron0/50 (0%)0/50 (0%)13/50 (26%)
Most frequent other events
Most frequent other events
EventAdmnistration of Granisetron
skin irritationSkin and subcutaneous tissue disorders6/50
constipationGastrointestinal disorders2/50
diarrheaGastrointestinal disorders1/50
hallucinationNervous system disorders1/50
dizzinessGeneral disorders1/50
headacheGeneral disorders1/50
EKG changesCardiac disorders1/50

Baseline characteristics

Age, Customized
Age, Customized(participants)Admnistration of Granisetron
18-21 years : female0
18-21 years : male0
22-29 years : female2
22-29 years : male0
30-39 years : female5
30-39 years : male0
40-49 years : female13
40-49 years : male0
50-59 years : female11
50-59 years : male2
60-69 years : female13
60-69 years : male0
70-79 years : female3
70-79 years : male0
80-89 years : female1
80-89 years : male0
Sex: Female, Male
Sex: Female, Male(Participants)Admnistration of Granisetron
Female48
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Admnistration of Granisetron
Hispanic or Latino1
Not Hispanic or Latino49
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Admnistration of Granisetron
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White47
More than one race1
Unknown or Not Reported1
Baseline Participants who completed study
Baseline Participants who completed study(Participants)Admnistration of Granisetron
18-21 years : female0
18-21 years : male0
22-29 years : female2
22-29 years : male0
30-39 years : female5
30-39 years : male0
40-49 years : female13
40-49 years : male0
50-59 years : female5
50-59 years : male2
60-69 years : female11
60-69 years : male0
70-79 years : female2
70-79 years : male0
80-89 years : female1
80-89 years : male0
08

Study locations

1 site
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 14, 2017

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02457195
Lead sponsor
Milton S. Hershey Medical Center
Responsible party
Piotr K Janicki MD, PhD (Professor of Anesthesiology, Milton S. Hershey Medical Center) — Principal investigator
First posted
May 29, 2015
Start date
Feb 2016
Primary completion
Feb 19, 2018
Completion
Feb 19, 2018
Results posted
Apr 16, 2019
Last update
Dec 18, 2019

Study contacts

Piotr K Janicki, MD
principal investigator · Penn State College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion